Radius Health reports positive data for ACTIVExtend BMD responder analysis for TYMLOS
Radius Health reported results from "Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density in Patients Treated with Abaloparatide Followed by Alendronate — Results from Phase 3 ACTIVExtend." BMD response rates increased in both the abaloparatide followed by alendronate group. March 17, 2018